BeOne Medicines AG (ONC) Shareholders & Insider Trades
BeOne Medicines shareholders at a glance
The largest holder of BeOne Medicines stock is Baker Bros. Advisors LP, with 8.8 million shares (8.02% of the company), worth about $3.17 billion as of September 25, 2026. The 10 largest holders together own 32.1%.
In Q2 2025, 1 institutional holdings reports listed 87,900 shares worth $21.30 million.
Insiders reported 68 transactions in the last two years: 49 sales worth $588.66 million and no purchases. The newest one on file is from May 13, 2026 (Lee Chan Henry, General Counsel).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2025); insider transactions on file through May 13, 2026.
BeOne Medicines AG
Shareholders Summary
2025Q2
Ownership by Type
Geographic Distribution
Largest BeOne Medicines shareholders
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Baker Bros. Advisors LP | 8.8 million | 8.02% | $3.2B |
| Baker Bros. Advisors LP | 8.8 million | 8.02% | $3.2B |
| PRIMECAP Management Co. | 5.0 million | 4.56% | $1.8B |
| Capital Research & Management Co. (International Investors) | 4.2 million | 3.83% | $1.5B |
| Fidelity Management & Research Co. LLC | 2.5 million | 2.26% | $891.0M |
| Capital Research & Management Co. (World Investors) | 2.2 million | 2.05% | $809.0M |
| Citadel Securities GP LLC | 1.4 million | 1.30% | $513.0M |
| Temasek Holdings Pte Ltd. | 845,729 | 0.77% | $304.0M |
| T. Rowe Price International Ltd. | 758,752 | 0.69% | $273.0M |
| BlackRock Institutional Trust Co. NA | 661,520 | 0.60% | $238.0M |
As of September 25, 2026.
BeOne Medicines institutional holdings by quarter
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2025 | 1 | 87,900 | $21.3M |
| Q4 2024 | 1 | 44,600 | $627,000 |
| Q2 2024 | 1 | 44,400 | $490,000 |
| Q1 2024 | 1 | 51,700 | $628,000 |
| Q4 2023 | 1 | 52,300 | $737,000 |
| Q3 2023 | 1 | 52,700 | $724,000 |
| Q2 2023 | 1 | 52,200 | $715,000 |
| Q1 2023 | 1 | 48,400 | $798,000 |
Shares and value held by institutions that file quarterly holdings reports (options not included).
BeOne Medicines insider trades
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Lee Chan Henry | May 13, 2026 | General Counsel | Conversion of Exercise of derivative security at price 159.03 - 213.32 per share. | $63,598 |
| Lee Chan Henry | May 13, 2026 | General Counsel | Sale at price 310.72 per share. | $103,159 |
| Lee Chan Henry | Apr 8, 2026 | General Counsel | Conversion of Exercise of derivative security at price 159.03 - 213.32 per share. | $63,598 |
| Lee Chan Henry | Apr 8, 2026 | General Counsel | Sale at price 311.59 per share. | $103,448 |
| Lee Chan Henry | Mar 11, 2026 | General Counsel | Conversion of Exercise of derivative security at price 159.03 - 213.32 per share. | $65,348 |
| Lee Chan Henry | Mar 11, 2026 | General Counsel | Sale at price 300.00 per share. | $102,300 |
| Lee Chan Henry | Feb 4, 2026 | General Counsel | Conversion of Exercise of derivative security at price 159.03 - 213.32 per share. | $317,721 |
| Lee Chan Henry | Feb 4, 2026 | General Counsel | Sale at price 348.79 - 350.00 per share. | $580,197 |
| Lee Chan Henry | Jan 7, 2026 | General Counsel | Conversion of Exercise of derivative security at price 159.03 - 213.32 per share. | $127,196 |
| Lee Chan Henry | Jan 7, 2026 | General Counsel | Sale at price 331.76 per share. | $220,289 |
| Oyler John Victor | Dec 16, 2025 | Chief Executive Officer | Sale at price 300.80 - 314.92 per share. | $30.7M |
| Lee Chan Henry | Dec 11, 2025 | General Counsel | Conversion of Exercise of derivative security at price 159.03 - 213.32 per share. | $127,196 |
Newest 12 of 68 insider transactions in the last two years.
Questions and answers
Who owns the most BeOne Medicines stock?
Baker Bros. Advisors LP, with 8.02% of the company (as of September 25, 2026). Next: Baker Bros. Advisors LP (8.02%) and PRIMECAP Management Co. (4.56%).
How many institutions own BeOne Medicines stock?
1 institutional holdings reports listed BeOne Medicines shares in Q2 2025, 87,900 shares in all worth $21.30 million.
Are BeOne Medicines insiders buying or selling the stock?
In the last two years insiders reported 49 sales and no purchases (68 transactions in all); the newest on file is from May 13, 2026.
